Eli Lilly
-
techMichael Dell’s Keynote: AI Is the New Enterprise Infrastructure
Michael Dell tells industry leaders that AI has moved into the operational core of business, urging a shift from cloud dependency to hybrid AI.
-
healthMajor Cochrane Review Questions Effectiveness of Alzheimer's Drugs
A Cochrane review finds amyloid-targeting drugs offer little benefit, sparking debate among experts and drugmakers.
-
healthRoche’s Blood Test for Alzheimer’s Wins European Approval
Roche and Eli Lilly’s Elecsys pTau217 blood test, the first to rule out Alzheimer’s, receives CE Mark approval in Europe.
-
healthHealth Canada Approves Second Drug to Slow Alzheimer's Progression
Donanemab, approved in Canada, offers hope by slowing early Alzheimer's decline, targeting amyloid plaques.
-
healthFDA Targets Copycat Weight-Loss Drugs, Limits Bulk Production
The FDA proposes removing Novo Nordisk and Eli Lilly's weight-loss drugs from a compounding list to curb unauthorized bulk production.
-
healthUS Prescription Drug Spending on Track to Exceed $1 Trillion, Fueled by GLP-1s
U.S. drug spending hit $915B in 2025, set to top $1T in 2026, driven by GLP-1 weight-loss drug demand. Eli Lilly and Novo Nordisk dominate the market.
-
techEli Lilly and Profluent Ink $2.25 Billion Deal for AI-Designed Genetic Medicines
Eli Lilly partners with AI firm Profluent in a major collaboration aiming to develop novel genetic medicines using advanced artificial intelligence for complex diseases.
-
healthMedicare Delays GLP-1 Weight-Loss Drug Program Amid Insurer Concerns
Medicare will offer GLP-1 weight-loss drugs via a temporary bridge program, delaying a new initiative due to insurer hesitations. Permanent integration remains uncertain.